Bioequivalency of doxycycline products

✍ Scribed by Edward J. Antal; James M. Jaffe; Holland I. Poust; John L. Colaizzi

• Book ID: 102409538
• Publisher: John Wiley and Sons
• Year: 1975
• Tongue: English
• Weight: 480 KB
• Volume: 64
• Category: Article
• ISSN: 0022-3549
• DOI: 10.1002/jps.2600641229

✦ Synopsis

The bioavailability of three different brands and three different dosage forms of doxycycline was studied in normal subjects. Single doses, equivalent to 200 mg of doxycycline, were administered to six subjects in a crossover design as the innovator's intravenous solution given orally (Treatment A), the innovator's capsule product (Treatment B), a noninnovator's capsule ' Vibramycin Intravenous, Lot 28286, Pfizer Laboratories. (This solution also contained 480 mg of ascorbic acid.)

Vibramycin Hyclate Capsules, Lot 31570, Pfizer Laboratories.